My lab is interested in understanding the functions of STING (Stimulator of IFN genes, a.k.a. TMEM173, MPYS and MITA) in innate and adaptive immune response. Specially, we are focusing on three questions: 1) Understanding the in vivo functions and mechanisms of STING in host defense against bacterial infections; 2) Deciphering STING-mediated innate immune signaling; 3) Understanding the molecular and cellular mechanisms of STING-mediated mucosal vaccine adjuvant activity of cyclic dinucleotides.
- Adjuvant Development;
- Host Defense Against Bacterial Infection;
- Innate Immune Signaling;
- Jin L, Waterman PM, Jonscher KR, Short CM, Reisdorph NA, Cambier JC.
MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals.
Mol Cell Biol. 2008 Aug;28(16):5014-26.
- Complete List of Publications
- Blaauboer SM, Mansouri S, Tucker HR, Wang HL, Gabrielle VD, Jin L
The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo.
Elife. 2015 Apr 21;4.
- Blaauboer SM, Gabrielle VD, Jin L
MPYS/STING-mediated TNF-alpha, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo.
J Immunol. 2014 Jan 1;192(1):492-502
- Jin L, Getahun A, Knowles HM, Mogan J, Akerlund LJ, Packard TA, Perraud AL, Cambier JC.
STING/MPYS mediates host defense against Listeria monocytogenes infection by regulating Ly6C(hi) monocyte migration.
J Immunol. 2013 Mar 15;190(6):2835-43
- Jin L, Hill KK, Filak H, Mogan J, Knowles H, Zhang B, Perraud AL, Cambier JC, Lenz LL
MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP.
J Immunol. 2011 Sep 1;187(5):2595-601
- Jin L, Xu LG, Yang IV, Davidson EJ, Schwartz DA, Wurfel MM, Cambier JC.
Identification and characterization of a loss-of-function human MPYS variant.
Genes Immun. 2011 Jun;12(4):263-9